Page 13 - Patient Groups News Today : Breaking News, Live Updates & Top Stories | Vimarsana

An old juristic measure by the biden administration. —— altruistic measure. a controversial new treatment for alzheimer's has been approved by regulators in the us. aducanumab targets the underlying cause of the disease rather than just easing symptoms. patient groups have campaigned for its approval, but it is a contentious decision. some experts and indeed the fda's independent advisory committee opposed its approval. 0ur medical editor, fergus walsh, reports. this is an historic moment in the battle against alzheimer's. for the first time, a drug has been approved which tackles not just...

The last several months. in conversations with the guatemalan president, i appreciate she is frank, she doesn't hold back and is willing to deal with these issues. that suggests a humility to speak truth to global counterparts will be important in foreign policy. it is going to be interesting. ed 0'keefe, joining us from guatemala city. we apologise for the quality of the line. it was a bit scratchy, wasn't it, but i think we got the gist of what ed was saying. a controversial new treatment for alzheimer's has been approved by regulators in the us. aducanumab targets the underlying cause of th...

Humanitarian aid, this $4 billion package over four years, one of the things bolstered will be security forces. security forces would be expected to disarm and tackle the international drug organisations and criminal organisations that run the drug routes north and the people trafficking routes north. but it would also be to stop, for example, the caravans of people we've seen trying to leave, who have been, you know, stopped from doing so with water cannon and tear gas and so on. you know, this is much more than simply an altruistic measure by the biden administration. will grant willgrant in...

Alzheimer's, but it is the first treatment to tackle the underlying mechanism which destroys brain function in this most cruel of conditions. and that alone makes this a landmark moment. the scientific reaction has been mixed, many welcoming this as a milestone, which will boost research. but others saying they believe this drug will only have marginal benefits. and it will take years yet to know just how good this drug is. patient groups here reckon that upwards of 100,000 people with early alzheimer's, mild symptoms, could benefit, and they will be pressing uk regulators for an early decisio...

This a landmark moment. thejury is still out on this drug. some doctors remain sceptical and us regulators have said everyone there who received it will need to be part of an ongoing trial and they have said they will pull approval in a few years if it fails to live up to the improvements in cognition the manufacturers are promising. here in the uk, patient groups reckon 100,000 people with early alzheimer's could benefit and they will be pressing regulators for a decision here but that is likely, for at least another year it will take. the likely cost is £35,000 per patient per year and appr...